ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2023
Recent drug development and treatments for fungal infections.
Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- In silico pathway-based subtractive proteomics for identifying novel drug targets in Candida albicans with structure-guided drug repurposing of aspartate-semialdehyde dehydrogenase inhibitors.Journal of molecular modeling · 2026Article
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Sensitive and eco-friendly extraction of antifungal drugs from artificial urine and saliva samples using MSPE coupled with HPLC-DAD.RSC advances · 2026Article
- Functional and molecular characterization ofJournal of medical microbiology · 2026Article
- Significant Activity of Pytren-2Q, a 2‑Quinoline Polyamine Compound, against High-Concern Human Pathogenic Fungi.ACS omega · 2026Article
- CARD9 Mutations in Patients with Invasive Fungal Infections.Mycopathologia · 2025Article
- Chemical Characteristics and Biological Potential ofLife (Basel, Switzerland) · 2025Article
- Raman Imaging of an Amphotericin B Potentiator in Single-CellThe journal of physical chemistry. B · 2025Article
- Functionalized Silver Nanoparticles as Multifunctional Agents Against Gut Microbiota Imbalance and Inflammation.Nanomaterials (Basel, Switzerland) · 2025Article
- Antifungal Agents' Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009-2023.Antibiotics (Basel, Switzerland) · 2025Article
- Candida albicans: the current status regarding vaginal infections.Applied microbiology and biotechnology · 2025Review
- Microbial evaluation of Melaleuca alternifolia essential oil for its antifungal activity against Trichophyton violaceum and its synergistic effects with ITZ and KTZ.Archives of dermatological research · 2025Article
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- AI in fungal drug development: opportunities, challenges, and future outlook.Frontiers in cellular and infection microbiology · 2025Review
- Baicalin promotes β-1,3-glucan exposure inFrontiers in cellular and infection microbiology · 2024Article
- Article
- Candida albicans and Antifungal Peptides.Infectious diseases and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections are now becoming a hazard to individuals which has paved the way for research to expand the therapeutic options available. Recent advances in drug design and compound screening have also increased the pace of the development of antifungal drugs. Although several novel potential molecules are reported, those discoveries have yet to be translated from bench to bedside. Polyenes, azoles, echinocandins, and flucytosine are among the few antifungal agents that are available for the treatment of fungal infections, but such conventional therapies show certain limitations like toxicity, drug interactions, and the development of resistance which limits the utility of existing antifungals, contributing to significant mortality and morbidity. This review article focuses on the existing therapies, the challenges associated with them, and the development of new therapies, including the ongoing and recent clinical trials, for the treatment of fungal infections. Advancements in antifungal treatment: a graphical overview of drug development, adverse effects, and future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.